Cerebrolysin Prices
Also known as FPF-1070
12 listings from 9 vendors, normalised to one honest price per milligram.
Cheapest per mg
$0.097/mg
At
BeiBangAn
Vendors
9
Sizes
30mg, 60mg Kit (10 vials), 60mg, 60mg Kit (5 vials), 760mg
Disclosure. Some vendors below are Peptul partners and pay us a commission when you buy through our link. Rows here are ordered by price per milligram only - paying us never moves a vendor up. Current discount codes are shown on the full price board.
Cerebrolysin price per mg by vendor
Prices last collected August 19, 2026.
| Vendor | Size | Price | Per mg | |
|---|---|---|---|---|
| BeiBangAnVerified COA | 60mg Kit (10 vials) | $58.00 | $0.097 | View |
| Hybiopeptides (HYB Peptides)Verified COA | 60mg Kit (10 vials) | $85.00 | $0.14 | View |
| Great Northern PeptidesVerified COA | 60mg Kit (5 vials) | $90.10 | $0.30 | View |
| VPeptide CanadaVerified COA | 760mg | $431.74 | $0.57 | View |
| Huaian Hanyou PeptideVerified COA | 60mg | $40.00 | $0.67 | View |
| Umbrella LabsVerified COAShips USOut of stock | 60mg | $49.99 | $0.83 | View |
| Luxara LabsVerified COA | 60mg | $61.27 | $1.02 | View |
| Red Leaf Research LabsVerified COA | 60mg | $64.87 | $1.08 | View |
| Luxara LabsVerified COA | 30mg | $39.64 | $1.32 | View |
| VPeptide CanadaVerified COA | 30mg | $50.45 | $1.68 | View |
| Certified PeptidesVerified COAShips US | 60mg | $110.00 | $1.83 | View |
About Cerebrolysin
- What it is
- Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids derived from purified pig brain protein, marketed in Russia, China, and parts of Europe and Asia for stroke, dementia, and traumatic brain injury. It is not approved by the FDA and remains investigational in the United States. Many randomized trials exist, but a Cochrane review found the evidence for acute ischemic stroke inconclusive.
- How it works
- It is believed to mimic endogenous neurotrophic factors and support neuron survival and repair, though the mechanism stays uncertain.
- Researched for
- Ischemic stroke; vascular dementia; Alzheimer disease; traumatic brain injury
- Half-life
- Not established
- Familiarity
- Intermediate
- Research evidence
- Human trials - phase 2 or 3
- Regulatory status
- Approved
- Key risk
- The main documented concern is a hypersensitivity reaction, with caution advised in people who have epilepsy or severe kidney disease.
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.